Status:
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborating Sponsors:
Pfizer
GE Healthcare
Conditions:
Parkinson Disease
Parkinsonian Syndrome
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane (\[123I\]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine ag...
Detailed Description
This is a multi-center, open-label study of short-term treatment with levodopa or cabergoline on striatal DATscan uptake in early Parkinson's disease. Approximately 120 Parkinson's disease subjects wi...
Eligibility Criteria
Inclusion
- The subject is aged 40 years or older.
- Written informed consent is obtained.
- Subjects have a clinical diagnosis of idiopathic Parkinson's disease.
- Hoehn and Yahr stages for subjects are I-II.
Exclusion
- The subject has atypical or drug-induced Parkinson's disease.
- The subject has dementia.
- The subject has clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.
- The subject is pregnant.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00129181
Start Date
January 1 2005
End Date
January 1 2007
Last Update
August 28 2009
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, Innsbruck Medical University
Innsbruck, Austria, 6020
2
Neurological Department, Wilhelminenspital
Vienna, Austria, 1160
3
Dept. of Neurology, University of Leipzig
Leipzig, Germany, 04103
4
Dept. of Neurology Marburg, Phillips-Univ.
Marburg, Germany, 35039